The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.g

Pulmonary fibrosis

Publications

Doi M, Okamoto Y, Yamauchi M, Naitou H, Shinozaki K

Bleomycin-induced pulmonary fibrosis after tumor lysis syndrome in a case of advanced yolk sac tumor treated with bleomycin, etoposide and cisplatin (BEP) chemotherapy.

International journal of clinical oncology. 2012;17(5):528-31

Godoy MC, Nonaka D, Raphael BG, Vlahos I

Diffuse ground-glass opacities in a patient with Hodgkin lymphoma and progressive respiratory failure.

Chest. 2008;134(1):207-12

Keijzer A, Kuenen B

Fatal pulmonary toxicity in testis cancer with bleomycin-containing chemotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(23):3543-4

Uzel I, Ozguroglu M, Uzel B, Kaynak K, Demirhan O, Akman C, Oz F, Yaman M

Delayed onset bleomycin-induced pneumonitis.

Urology. 2005;66(1):195

Sleijfer S

Bleomycin-induced pneumonitis.

Chest. 2001;120(2):617-24

Giaccone G, Risio M, Bonardi G, Calciati A

Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin: a case report.

Tumori. 1986;72(3):331-3